Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Amr I. Al Abbas"'
Autor:
Melissa E. Hogg, Jeffrey D. Borrebach, Amer H. Zureikat, Johanna E. Bellon, Henry A. Pitt, Herbert J. Zeh, Amr I. Al Abbas
Publikováno v:
Journal of Gastrointestinal Surgery. 25:1503-1511
Pancreatoduodenectomy (PD) is often performed in frail patients and is associated with significant morbidity. The five-factor modified frailty index (mFI-5) has been utilized to predict adverse postoperative outcomes, but has not been tested in PD. W
Autor:
Jae Pil Jung, Alessandro Paniccia, Mazen S. Zenati, Herbert J. Zeh, Kenneth K.W. Lee, Nathan Bahary, Melissa E. Hogg, Ana Gleisner, Amr I. Al Abbas, David L. Bartlett, Amer H. Zureikat
Publikováno v:
Annals of Surgical Oncology. 27:2961-2971
Neoadjuvant therapy (NT) is a growing strategy in localized head pancreatic adenocarcinoma (PDC). However, a significant portion of NT patients do not reach resection due to disease progression or performance status decline. We sought to identify pre
Autor:
Mazen S. Zenati, Amer H. Zureikat, Melissa E. Hogg, Amr I. Al Abbas, Herbert J. Zeh, Jae Pil Jung, Caroline J. Reiser, Ahmad Hamad
Publikováno v:
Ann Surg Oncol
INTRODUCTION: Optimal cut-offs for CA19-9 response after neoadjuvant therapy (NT) for pancreatic adenocarcinoma (PDAC) are not well characterized. This study aims to analyze the relationship of serum CA19-9 with other markers of response and identify
Publikováno v:
Journal of Gastrointestinal Surgery. 24:2259-2268
Higher MELD scores correlate with adverse operative outcomes regardless of the presence of liver disease, but their impact on pancreatectomy outcomes remains undefined. We aimed to compare 30-day adverse postoperative outcomes of patients undergoing
Autor:
Virginia Falvello, Nathan Bahary, Herbert J. Zeh, Amer H. Zureikat, Ashika Mani, Mazen S. Zenati, Amr I. Al Abbas, Aatur D. Singhi, Melissa E. Hogg
Publikováno v:
Journal of surgical oncologyREFERENCES.
BACKGROUND AND OBJECTIVES Ampullary adenocarcinoma (AA) is classified by immunohistochemical (IHC) subtypes into intestinal (IN), pancreatobiliary (PB), and ambiguous (AM). The impact of adjuvant therapy on IHC subtype and disease stage is unclear. W
Autor:
Amr I. Al Abbas, Melissa E. Hogg
Publikováno v:
Annals of Surgical Oncology. 27:2015-2016
Autor:
Pranav Murthy, Amr I. Al Abbas, Mazen S. Zenati, Nathan Bahary, Michael T. Lotze, Amer H. Zureikat, Brian A. Boone, Caroline J. Rieser, Herbert J. Zeh
Publikováno v:
Ann Surg Oncol
BACKGROUND. The systemic immune-inflammation index (SII), calculated using absolute platelet, neutrophil, and lymphocyte counts, has recently emerged as a predictor of survival for patients with pancreatic ductal adenocarcinoma (PDAC) when assessed a
Autor:
Amer H. Zureikat, Amr I. Al Abbas, Melissa E. Hogg, Herbert J. Zeh, Jae Pil Jung, Ahmad Hamad, Caroline J. Rieser, Mazen S. Zenati
Publikováno v:
Annals of Surgical Oncology. 27:965-965
In the original article, Caroline J. Rieser’s last name is spelled wrong. It is correct as reflected here.
Autor:
Ahmad Hamad, Melissa E. Hogg, Caroline J. Rieser, Amr I. Al Abbas, Amer H. Zureikat, Nathan Bahary, Mazen S. Zenati, Herbert J. Zeh
Publikováno v:
Annals of surgical oncology. 25(12)
Serum carbohydrate antigen 19-9 (CA19-9) correlates with response to therapy and overall survival (OS) for patients with pancreatic ductal adenocarcinoma (PDAC). This study aimed to define the chronologic relationship between CA19-9 elevation and rad
Autor:
Amer H. Zureikat, Herbert J. Zeh, Amr I. Al Abbas, Ahmad Hamad, Caroline J. Reiser, Melissa E. Hogg, Mazen S. Zenati
Publikováno v:
Journal of the American College of Surgeons. 227:S248-S249